Search Results - "López Miranda, Elena"

Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments by Cortés, Alfonso, Casado, José L., Longo, Federico, Serrano, Juan J., Saavedra, Cristina, Velasco, Héctor, Martin, Adrián, Chamorro, Jesús, Rosero, Diana, Fernández, María, Gion, María, Martínez Jáñez, Noelia, Soria Rivas, Ainara, Alonso Gordoa, Teresa, Martínez Delfrade, Íñigo, Lage, Yolanda, López Miranda, Elena, Olmedo, María E., Reguera Puertas, Pablo, Gajate, Pablo, Molina Cerrillo, Javier, Guerra Alia, Eva, Fuentes Mateos, Raquel, Romero, Beatriz, Rodríguez-Domínguez, Mario J., Vallejo, Alejandro, Carrato, Alfredo

“…Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in…”
Get full text

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study by Cortés, Alfonso, López-Miranda, Elena, Fernández-Ortega, Adela, Carañana, Vicente, Servitja, Sonia, Urruticoechea, Ander, Lema-Roso, Laura, Márquez, Antonia, Lazaris, Alexandros, Alcalá-López, Daniel, Mina, Leonardo, Gener, Petra, Rodríguez-Morató, Jose, Antonarelli, Gabriele, Llombart-Cussac, Antonio, Pérez-García, José, Cortés, Javier

“…To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations…”
Get full text

A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer by Sampayo-Cordero, Miguel, Miguel-Huguet, Bernat, Malfettone, Andrea, López-Miranda, Elena, Gion, María, Abad, Elena, Alcalá-López, Daniel, Pérez-Escuredo, Jhudit, Pérez-García, José Manuel, Llombart-Cussac, Antonio, Cortés, Javier

“…De-escalation trials in oncology evaluate therapies that aim to improve the quality of life of patients with low-risk cancer by avoiding overtreatment…”
Get full text

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature by Albarrán, Víctor, Chamorro, Jesús, Pozas, Javier, San Román, María, Rosero, Diana Isabel, Saavedra, Cristina, Gion, María, Cortés, Alfonso, Escalera, Elena, Guerra, Eva, López Miranda, Elena, Fernández Abad, María, Martínez Jañez, Noelia

“…PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic…”
Get full text

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design by Sampayo-Cordero, Miguel, Miguel-Huguet, Bernat, Pérez-García, José, Páez, David, Guerrero-Zotano, Ángel L., Garde-Noguera, Javier, Aguirre, Elena, Holgado, Esther, López-Miranda, Elena, Huang, Xin, Malfettone, Andrea, Llombart-Cussac, Antonio, Cortés, Javier

“…Non-inferiority (NI) analysis is not usually considered in the early phases of clinical development. In some negative phase II trials, a post-hoc NI analysis…”
Get full text

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer by Jhaveri, Komal L, Bellet, Meritxell, Turner, Nicholas C, Loi, Sherene, Bardia, Aditya, Boni, Valentina, Sohn, Joohyuk, Neilan, Tomas G, Villanueva-Vázquez, Rafael, Kabos, Peter, García-Estévez, Laura, López-Miranda, Elena, Pérez-Fidalgo, J Alejandro, Pérez-García, Jose M, Yu, Jiajie, Fredrickson, Jill, Moore, Heather M, Chang, Ching-Wei, Bond, John W, Eng-Wong, Jennifer, Gates, Mary R, Lim, Elgene

“…Giredestrant is an investigational next-generation, oral, selective estrogen receptor antagonist and degrader for the treatment of estrogen receptor-positive…”
Get full text

Etirinotecan pegol for the treatment of breast cancer by López-Miranda, Elena, Cortés, Javier

“…Advanced breast cancer is incurable for most patients with limited therapeutic options. As such, there is a critical need for new and novel agents that lack…”
Get more information

High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features by Rosa-Rosa, Juan Manuel, Caniego-Casas, Tamara, Leskela, Susanna, Cristobal, Eva, González-Martínez, Silvia, Moreno-Moreno, Esther, López-Miranda, Elena, Holgado, Esther, Pérez-Mies, Belén, Garrido, Pilar, Palacios, José

“…Characterisation of molecular alterations of pleomorphic lobular carcinoma (PLC), an aggressive subtype of invasive lobular carcinoma (ILC), have not been yet…”
Get full text

Strongyloides in bronchoalveolar lavage fluid: practical implications in the COVID-19 era by Norman, Francesca F, Chamorro, Sandra, Braojos, Francisco, López-Miranda, Elena, Chamorro, Jesús, González, Irene, Martín, Oihane, Pérez-Molina, José-Antonio

“…Latent infections caused by Strongyloides sp. may become symptomatic years after initial exposure in endemic areas especially in specific contexts such as…”
Get full text

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors by Saavedra, Cristina, Vallejo, Alejandro, Longo, Federico, Serrano, Juan José, Fernández, María, Gion, María, López-Miranda, Elena, Martínez-Jáñez, Noelia, Guerra, Eva, Chamorro, Jesús, Rosero, Diana, Velasco, Héctor, Martín, Adrián, Carrato, Alfredo, Casado, José Luis, Cortés, Alfonso

“…Few data are available about the immune response to mRNA SARS-CoV-2 vaccines in patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors…”
Get full text

Cytological and molecular characterization of secretory breast carcinoma by Carretero‐Barrio, Irene, Santón, Almudena, Caniego Casas, Tamara, López Miranda, Elena, Reguero‐Callejas, Maria Eugenia, Pérez‐Mies, Belén, Benito, Amparo, Palacios, José

“…Secretory breast carcinoma is a rare neoplasm, histologically well‐characterized, and secondary to ETV6‐NTRK3 gene fusion, whose cytological features are…”
Get full text

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial by López-Miranda, Elena, Pérez-García, José Manuel, Di Cosimo, Serena, Brain, Etienne, Ravnik, Maja, Escrivá-de-Romaní, Santiago, Vidal, Maria, Gligorov, Joseph, Borštnar, Simona, Calabuig, Laura, Sampayo-Cordero, Miguel, Malfettone, Andrea, Llombart-Cussac, Antonio, Suter, Thomas M, Cortés, Javier

“…The paper assesses the dose-limiting toxicities and the maximum tolerated dose (MTD) of trastuzumab emtansine (T-DM1) combined with non-pegylated liposomal…”
Get full text

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study by López González, Ana, Del Barco Berrón, Sonia, Grau, Isabel, Galan, Maria, Castelo Fernández, Beatriz, Cortés, Alfonso, Sánchez Rovira, Pedro, Martinez-Bueno, Alejandro, Gonzalez, Xavier, García, Almudena, Gener, Petra, Mina, Leonardo, Alcalá-López, Daniel, Sampayo, Miguel, Cortés, Javier, Pérez-Garcia, José Manuel, Llombart-Cussac, Antonio, López-Miranda, Elena

“…Luminal advanced breast cancer (ABC) patients eventually progress on endocrine therapy. REVERT aimed to explore whether eribulin could restore endocrine…”
Get full text

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study by de la Cruz-Merino, Luis, Gion, María, Cruz-Jurado, Josefina, Quiroga, Vanesa, Andrés, Raquel, Moreno, Fernando, Alonso-Romero, Jose, Ramos, Manuel, Holgado, Esther, Cortés, Javier, López-Miranda, Elena, Henao-Carrasco, Fernando, Palazón-Carrión, Natalia, Rodríguez, Luz, Ceballos, Isaac, Casas, Maribel, Benito, Sara, Chiesa, Massimo, Bezares, Susana, Caballero, Rosalia, Jiménez-Cortegana, Carlos, Sánchez-Margalet, Víctor, Rojo, Federico

“…The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative…”
Get full text

Abstract P5-18-07: Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer by Neilan, Tomas G, Villanueva-Vázquez, Rafael, Bellet, Meritxell, López-Miranda, Elena, García-Estévez, Laura, Kabos, Peter, Bond, John, Gates, Mary R, Chang, Ching-Wei, Boni, Valentina

“…Background Targeting the activity of the estrogen receptor and/or estrogen synthesis is a standard primary treatment for eligible patients with estrogen…”
Get full text

Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study by Cortés-Salgado, Alfonso, Serrano, Juan José, Cordero Pereda, David, Menacho, Miriam, Del Rey, José Manuel, del Campo-Albendea, Laura, Saavedra, Cristina, Chamorro, Jesús, Rosero, Diana, Sotoca, Pilar, Guillén-Ponce, Carmen, Guerra, Eva, Fernández-Abad, María, López-Miranda, Elena, Martínez-Jáñez, Noelia, Gion, María, Salazar, María Teresa, Agudo-Quílez, Pilar, Garrido, Pilar, Alonso Salinas, Gonzalo Luis

“…BRCA1/2 genes play a critical role in genome stability and DNA repair. In animal models, loss of cardiomyocyte-specific BRCA1/2 is associated with DNA damage,…”
Get full text

Abstract OT1-12-09: Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa) by Gregori, Joaquín Gavilá, Miranda, Elena López, Escrivá-de-Romaní, Santiago, Rodríguez, Begoña Jiménez, Novoa, Silvia Antolín, Morales, Luis Fernández, Calvo, Elena Galve, Cortijo, Lucía González, Martorell, Antonia Perelló, Ruiz, Julián Lagunar, Santiago, Santiago González

“…Type: Trial in progress. Introduction: Sequential intravenous (IV) treatment with pertuzumab and trastuzumab is effective in disrupting HER2 signalling in…”
Get full text

Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial by Pérez-García, José M., Llombart-Cussac, Antonio, Gion, María, Curigliano, Giuseppe, López-Miranda, Elena, Alonso, José L., Bermejo, Begoña, Calvo, Lourdes, Carañana, Vicente, de. la Cruz Sánchez, Susana, Márquez Vázquez, Raúl, Prat, Aleix, Ruiz Borrego, Manuel, Sampayo-Cordero, Miguel, Seguí-Palmer, Miguel Á., Soberino, Jesus, Malfettone, Andrea, Schmid, Peter, Cortés, Javier

“…Pembrolizumab has modest activity if used in patients with hormone-receptor–positive (HR+), HER2-negative, previously treated metastatic breast cancer (BC)…”
Get full text

Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC) by Ciruelos, Eva, Saura, Cristina, González-Farré, Xavier, Bofill, Javier Salvador, Vidal, Maria, Blancas, Isabel, López-Miranda, Elena, Iglesias, Maria, Arumi, Miriam, Margelí, Mireia, Pulido, Catarina, Morales, Serafin, Henao, Fernando, Sánchez, Pilar, Alves, Sara, Branco, Diogo, Gasent, Joan Manel, Sánchez-Rovira, Pedro, Godoy, Ana, Passos-Coelho, José L., Escrivá-de-Romaní, Santiago, Ferrero-Cafiero, Juan M, Pascual, Tomás, Prat, Aleix

“…Background HR+/HER2-negative BC represents ∼70% of all newly diagnosed breast tumors. BC is a clinically and biologically heterogeneous disease where intrinsic…”
Get full text

Abstract OT-28-05: Solti-1718 NEREA trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-Enriched (HER2-E) advanced breast cancer (BC) by Saura, Cristina, Ciruelos, Eva, Vidal, Maria, Garrigós, Laia, Margelí, Mireia, Morales, Serafin, Gonzalez-Farré, Xavier, Bofill, Javier Salvador, Blancas, Isabel, Gasent, Joan M, López-Miranda, Elena, Godoy, Ana, Iglesias, Maria, Sánchez-Rovira, Pedro, Hernao, Fernando, Gallegos, Isabel, Pulido, Catarina, Alves, Sara, Branco, Diogo, Passos-Coelho, José, Escrivá-de-Romaní, Santiago, Ferrero-Cafiero, Juan M, Villagrasa, Patricia, Prat, Aleix

“…Background: HR+/HER2-negative BC represent ∼70% of all newly diagnosed breast tumors. BC is a clinically and biologically heterogenous disease where intrinsic…”
Get full text